Bridge Bio Starts Trial of Novel EGFR Inhibitor for NSCLC with Mutations

Bridge Biotherapeutics of Korea has started a Phase I/II trial of a novel EGFR inhibitor in non-small cell lung cancer (NSCLC) patients with a specific mutation. BBT-176 will be tested in NSCLC patients who progressed following prior therapy with an EGFR TKI agent. BBT-176 is designed to inhibit the signaling pathway of EGFR with C797S mutations, which causes resistance to osimertinib (Tagrisso). In China , Bridge Bio is a resident company of JLABS @ Shanghai, a Johnson & Johnson incubator. More details.... Stock Symbol: (KOSDAQ: 288330) Share this with colleagues: // //